BioCardia, Inc. (BCDA) stock
BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.92−0.01 (-0.91%)
Close on Nov 11, 2026Market cap $13.95MP/E –Yield –
BioCardia EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
BioCardia's EPS for the twelve months ending Jun 30, 2026 was -$0.77. For fiscal 2021 it was -$0.75. The highest annual figure on record is $4.44 in fiscal 2011.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | -$0.75 | – |
| FY2020 | Dec 31, 2020 | -$1.48 | – |
| FY2019 | Dec 31, 2019 | -$2.61 | – |
| FY2018 | Dec 31, 2018 | -$3.28 | – |
| FY2017 | Dec 31, 2017 | -$2.90 | – |
| FY2016 | Dec 31, 2016 | -$11.07 | – |
| FY2015 | Dec 31, 2015 | -$38.61 | – |
| FY2014 | Dec 31, 2014 | $0.00 | – |
| FY2013 | Dec 31, 2013 | $0.00 | – |
| FY2012 | Dec 31, 2012 | $0.00 | -100.0% |
| FY2011 | Dec 31, 2011 | $4.44 | – |
| FY2010 | Dec 31, 2010 | -$5.55 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.13 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.21 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.19 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.24 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.40 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.59 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.50 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.61 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.88 | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.35 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.38 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.79 | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.52 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.17 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.17 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.17 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.14 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.19 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.20 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.16 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.20 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.18 | – |
| Q4 FY2020 | Dec 31, 2020 | -$0.22 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.30 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.46 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.67 | – |
| Q4 FY2019 | Dec 31, 2019 | -$0.52 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.63 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.77 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.86 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.85 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.83 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.76 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.81 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.82 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.72 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.72 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.72 | – |
| Q3 FY2016 | Sep 30, 2016 | -$18.54 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?